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a b s t r a c t
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) continues to be a threat to human health in
the Middle East. Development of countermeasures is ongoing; however, an animal model that faithfully
recapitulates human disease has yet to be deﬁned. A recent study indicated that inoculation of common
marmosets resulted in inconsistent lethality. Based on these data we sought to compare two isolates of
MERS-CoV. We followed disease progression in common marmosets after intratracheal exposure with:
MERS-CoV-EMC/2012, MERS-CoV-Jordan-n3/2012, media, or inactivated virus. Our data suggest that
common marmosets developed a mild to moderate non-lethal respiratory disease, which was quantiﬁ-
able by computed tomography (CT), with limited other clinical signs. Based on CT data, clinical data, and
virological data, MERS-CoV inoculation of common marmosets results in mild to moderate clinical signs
of disease that are likely due to manipulations of the marmoset rather than as a result of robust viral
replication.
Published by Elsevier Inc.
Introduction
Infection with Middle East Respiratory Syndrome Coronavirus
(MERS-CoV) has been associated with Middle East Respiratory
Syndrome commonly known as MERS, a respiratory syndrome
with acute severe hypoxic respiratory failure often accompanied
by renal failure (Arabi et al., 2014; Assiri et al., 2013; Zaki et al.,
2012). As of March, 2015 there have been approximately 1000
laboratory conﬁrmed cases reported with a 36% case fatality rate
(http://www.who.int/csr/disease/coronavirus_infections/). Consid-
ering the geographical location of MERS and the Hajj pilgrimage
which draws an estimated 2.5 million visitors, roughly 1.8 million
of whom travel internationally (http://www.cdsi.gov.sa/english/
index.php?option=com_docman&Itemid=173) MERS-CoV repre-
sents a global health risk. Common signs and symptoms of MERS
include fever, cough, shortness of breath, and myalgia. Gastro-
intestinal signs are also frequently observed which include vomit-
ing, diarrhea, and abdominal pain (Assiri et al., 2013). Often, MERS
patients also have underlying comorbidities such as diabetes,
hypertension, and chronic cardiac or renal disease (Assiri
et al., 2013).
To guide development of MERS countermeasures, an appro-
priate animal model must be identiﬁed and characterized. Ideally,
a laboratory animal model would demonstrate clinical signs
consistent with all aspects of human disease. As with most
infectious diseases, mice have been evaluated as a potential MERS
model for pathogenesis and countermeasure screening. Balb/c and
STAT-1 knockout mice did not develop signs of disease, such as
weight loss, nor could infectious virus be recovered from lung
homogenates (Coleman et al., 2014). Zhao et al. developed a
murine model for MERS by transduction of the respiratory tract
with the putative MERS-CoV receptor, human dipeptidyl peptidase
4 (DPP4 or CD26), using an adenovirus construct (Zhao et al.,
2014). Infected mice developed limited clinical signs including a
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small degree of weight loss. Histopathological analysis found
peribronchial and perivascular lymphoid inﬁltrates which later
progressed to an interstitial pneumonia. Nearly 6 log10 plaque
forming units (PFU)/g of infectious virus could be detected in the
lungs of infected DPP4 transduced mice (Zhao et al., 2014). The
DPP4 transduced mouse model has been used to evaluate counter-
measures and pathogenesis (Channappanavar et al., 2014a, 2014b).
Nonhuman primate (NHP) models are considered to be essen-
tial to understanding pathogenesis and evaluating countermea-
sures. Results from several challenge studies of MERS-CoV in
rhesus monkeys (Macaca Mulatta) have varied between labora-
tories. The ﬁrst published NHP model used rhesus monkeys
inoculated via multiple routes and evaluated for virological,
immunological, and histopathological changes up to 6 days post-
inoculation (de Wit et al., 2013). NHPs demonstrated signs of
pneumonia and virus could be detected in tissues and mucous
membranes by quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR), but attempts to determine the load of
infectious virus was not reported. A follow up study demonstrated
that administration of interferon-alpha2b and ribavirin reduced
viral burden and lessened disease (Falzarano et al., 2013). Results
from a natural history study of MERS-CoV-infected rhesus mon-
keys indicated that intratracheal inoculation induced a non-lethal
disease with limited pathology observed in recovering animals at
28 days post-inoculation and infectious virus could be recovered
from lung but not other tissues assayed (Yao et al., 2014). Standard
radiological examination revealed lung inﬁltrates at days 3 and
5 post-inoculation, suggesting virus-induced lung disease. More
recently, Falzarano et al. described multiple route inoculation of
the common marmoset (Callithrix jacchus) in which transcriptional
changes indicating induction of immune, inﬂammatory, and repair
pathways were cataloged and partial lethality was observed
(Falzarano et al., 2014).
Here we characterize intratracheal (IT) inoculation of MERS-
CoV into common marmosets as a model for MERS and to
determine differences between two common isolates of MERS-
CoV, MERS-CoV-Jordan-n3/2012 virus and MERS-CoV-EMC/2012
virus. We inoculated 4 groups of marmosets and followed disease
progression by periodic physical exams that included computed
tomography (CT). Previously, positron emission tomography with
computed tomography (PET)/CT has been used to evaluate tuber-
culosis therapies in common marmosets (Via et al., 2013), disease
progression in monkeypox-virus-inoculated cynomolgus monkeys
(Dyall et al., 2011), and inﬂuenza-A-virus-inoculated ferrets
(Jonsson et al., 2012). CT has two distinct advantages when
compared to standard x-ray radiography 1) CT provides three
dimensional data, and 2) CT data can be quantiﬁed, which allows
unbiased comparisons (Elke et al., 2013; Li et al., 2013; Romanova
et al., 2014).
Results
An ex-vivo experiment with marmoset lung and kidney pri-
mary cultures found that these tissues could support MERS-CoV
replication; this suggested that common marmosets might be
developed as a suitable animal model for MERS (Fig. 1). Therefore,
we sought to determine if intratracheal inoculation of marmosets
would result in disease presentation similar to human disease. The
experimental design is shown in Fig. 2. Two pre-inoculation
baseline CT's were performed to establish normal lung volumes
and any pre-existing anomalies.
MERS-CoV-Jordan-n3/2012 virus (MERS-JOR, Genbank
KC776174) and MERS-CoV-EMC/2012 virus (MERS-EMC, Genbank
JX869059) were obtained and propagated as described in Materi-
als and Methods. To ensure that no gross cross-contamination of
the MERS-CoV stocks used for the marmoset experiments
occurred during preparation, the spike protein of each stock was
sequenced and compared to reference sequences (Cotten et al.,
2013; Frey et al., 2014). The spike region was chosen for compar-
ison due to high diversity associated with viral glycoproteins.
Strain-speciﬁc differences found in MERS-JOR and MERS-EMC
reference sequences were maintained in our stocks (Table 1),
indicating that no gross cross-contamination occurred. Three
single nucleotide polymorphisms (SNPs) were seen in our stocks,
two in MERS-EMC and one in MERS-JOR. BLASTX alignments
indicate that two of these SNPs lead to changes in the S2 protein
sequence. The MERS-JOR stock had a T to C change at position
2636 which induced an I839T change in S2. Two changes were
observed in MERS-EMC C to T at position 2604 that did not alter
amino acid sequence and a C to A change at 3044 which resulted
in a N1016T change in S2. Changes in the S2 region seen here are
likely a result of serial passage in cell culture (Frey et al., 2014).
Clinical signs and hematology indicate mild disease
Body temperature, peripheral oxygen saturation, respiratory
rate, and overall condition were evaluated at each physical exam.
No increases in body temperatures above normal ranges were
observed; subjects maintained peripheral oxygenation throughout
the study, and respiratory rates increased above normal range
sporadically throughout the study (Fig. 3A). Tremors were noted
on daily observations including and between days 3 and 9 post-
inoculation, but were not consistently observed (data not shown).
Subjects underwent blood withdrawal on days 0, 4 or 5, and at
necropsy to determine if hematological parameters indicated
changes consistent with disease. Day 4 or 5 was chosen based
on our data from MERS-JOR inoculated rhesus monkeys which
demonstrated a peak in lung disease at day 5 post-inoculation by
CT (manuscript in preparation). Subjects did not develop clinically
signiﬁcant changes in total white blood cell count, lymphocyte
number, monocyte number, or neutrophil number on day 4 or 5
post-inoculation and remained within the normal range, as
indicated by shaded gray area (Fig. 3B). Together, these data
indicate that subjects did not develop systemic clinical disease.
To determine if virus was disseminating or shedding, whole
blood, oropharyngeal, rectal swabs, and fecal samples from mock
and inactivated virus subjects, 2 subjects per group, were collected
on days 21, 8, 1, 3, 5, 7, 14 or 15, and 25. MERS Jordan subjects
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Fig. 1. Ex-vivo analysis of primary cells. Cells were isolated from lung, kidney, and
bronchoalveolar lavage (BAL), and one-step growth kinetics were performed as
described in Materials and Methods. Lung, Kidney and BAL demonstrate that
MERS-CoV is able to replicate to at least 4 log10 PFU/mL.
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were swabbed on days 21, 8, 1 (n¼1), 2 (n¼2), 3(n¼1), 4
(n¼2), 5(n¼1), 6 (n¼2), 7(n¼1), 8(n¼2) 14(n¼3) and 32 and
MERS-EMC exposed subjects were swabbed on days 21(n¼3), -8
(n¼3), 1(n¼3), 3 (n¼3), 5(n¼3), 7(n¼3), 14(n¼3), and 25 (n¼3)
as outlined in Fig. 2. These samples were assayed by qRT-PCR as
described in Materials and Methods. All samples were negative for
MERS-CoV, suggesting that virus did not disseminate nor was
shed. Furthermore, plaque assays were performed on necropsy
tissues and no infectious virus could be detected. Virus isolation
was attempted using lung homogenates for two sequential pas-
sages on Vero cells; no infectious virus could be detected.
Antibody response to MERS-CoV inoculation
Fluorescent reduction neutralizing assays were performed to
determine if marmosets developed an antibody response to MERS-
CoV (Fig. 4). Subjects inoculated with MERS-JOR developed a low
antibody titer to MERS-CoV with an average titer of 1:100 across
the group at study end, day 25–32 post-inoculation. Animals
inoculated with MERS-EMC developed an antibody titer of 1:80
for all 3 subjects. Media only, and inactivated virus did not develop
detectable neutralizing antibody responses to MERS-CoV.
CT suggests moderate lung disease
Qualitative assessment of the imaging data indicates that
MERS-CoV inoculated marmosets developed lung disease that
mainly affected the medial and caudal regions of the lung. Lung
abnormalities could be observed in media-only and the inacti-
vated virus inoculation groups, with the inactivated virus stimu-
lating increased lung abnormalities when compared to the media
only mock inoculated subjects (Fig. 5A). Lung inﬁltrates presenting
as air bronchograms did not completely clear by end of study
(Fig. 5B).
More importantly, quantitative assessment of abnormal lung
volume data supported the qualitative assessment. The quantita-
tive assessment suggests that mock inoculated subjects developed
a short lived response that was observed one day post-inoculation
but returned to near baseline by the day 7 CT and remained near
that volume throughout the course of the study. Subjects inocu-
lated with inactivated virus demonstrated increased abnormal
lung volumes when compared to the media only group, but not
as elevated as the groups that received live virus. MERS-CoV
inoculated groups demonstrated increasingly abnormal lung
volumes beginning day 1 post-inoculation in an individual depen-
dent manner that did not completely resolve by study end (Fig. 5C
and D). Comparison of the mean peak values of diseased lung
volume and percent relative change of abnormal lung volume for
each group indicated no statistically signiﬁcant difference
(unpaired t-test) between the virus isolates (Fig. 5E and F). When
the peak diseased lung volume of the infectious MERS-EMC
receiving group is compared to the mock infected the p-
value¼0.026 and when compared to the γ-irradiated virus receiv-
ing group it is p¼0.548. Comparison of the MERS-JOR group to the
control groups indicates a similar pattern p¼0.057 and p¼0.1245,
respectively. Comparison of the % fold change in diseased lung
volume between the MERS-EMC and mock group gave p¼0.0049
and the γ-irradiated virus receiving group was 0.0195. Comparison
of the % fold change in diseased lung volume between the MERS-
JOR and mock group gave p¼0.2102 and p¼0.1591. The data
indicate that, in common marmosets, the genetic sequence differ-
ences between the isolates do not impact disease progression as
indicated by changes in diseased lung volume and that the MERS
virion itself can induce an inﬂammatory response. However, a
signiﬁcant difference was observed between the MERS-EMC group
and the mock exposed group when compared by fold change of
diseased lung volume, which likely reﬂects the small group sizes.
Differences in temporal progression were observed between the
individual subjects that did not segregate by virus isolate.
One subject in the MERS-EMC inoculated group appeared to
develop a secondary infection observed by CT that increased to
study end, day 25 post-exposure. However, no infectious virus
could be recovered, suggesting an opportunistic infection either
due to repeated manipulations or effects of MERS-CoV.
Pathology supports CT ﬁndings
At necropsy, lung lesions included multifocal to coalescing
interstitial pneumonia with consolidation of the dorsocaudal lung
lobe in the MERS-CoV inoculated animals (Fig. 6). Gross pathology
of MERS-CoV infected subjects revealed no to moderate changes.
These changes include interstitial multifocal to coalescing moderate
pneumonia as shown in Fig. 6A. Histopathological examination of
select lymphoid tissues revealed mild lymphoid hyperplasia, with
Fig. 2. Experimental study design. Four groups of common marmosets were inoculated with virus culture growth media (mock), 5107 PFU of γ-irradiated (inactivated)
MERS-JOR, or MERS-EMC, 5107 PFU of MERS-JOR, or 5107 PFU MERS-EMC. Procedures were performed when indicated.
Table 1
MERS-CoV Spike Sequence comparison.
Spike
alignment
position
MERS-JOR reference
sequence (Genbank
KC776174)
MERS-
JOR
study
stock
MERS-EMC reference
sequence (Genbank
JX869059)
MERS-
EMC
study
stock
281 G G U U
580 C C U I
902 G G U U
2604 C U C C
2636 U U U C
3044 A A G G
3249 C C G G
3285 G G U U
3472 U U C C
3591 C C U U
3669 C C U U
3753 C C U U
3792 C C U U
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medullary histiocytosis of the mandibular and tracheobronchial
lymph nodes in several of the MERS-CoV inoculated subjects, while
the control animals showed minimal changes. Examination of
representative lung tissue samples showed interstitial lymphohis-
tiocytic pneumonia with type II pneumocyte and bronchial asso-
ciated lymphoid tissue (BALT) hyperplasia and a few syncytia were
observed in the MERS-CoV inoculated animals (Fig. 6B and D). In
addition, the lung lesions observed in the MERS-CoV inoculated
subjects are consistent with a chronic respiratory disease. In
general, the gross and histopathological ﬁndings in the lung tissue
did somewhat correspond with the CT ﬁndings. Examination of
representative lung tissue from a single subject that received MERS-
JOR and demonstrated the greatest increase in diseased lung
volume as seen by CT did not differ grossly or histologically from
the other subjects. No signal was detected for the presence of
MERS-CoV antigen by immunohistochemistry (IHC) performed on
the lung tissue sections of the infected subjects.
Discussion
Ideally, an animal model for MERS will recapitulate the key
features of the human disease in the severe form. Therefore, an
ideal MERS model might result in lethal disease with severe
bronchopneumonia and extrapulmonary complications such as
renal failure. With the use of CT, we observed that IT inoculation of
common marmosets with MERS-JOR or MERS-EMC isolates
resulted in a non-lethal disease characterized by limited clinical
signs and moderate consolidative lung pathology that did not
completely resolve by study end. No difference in clinical signs
was observed between the two isolates or control subjects, nor
could we detect MERS-CoV genome using a genome speciﬁc qRT-
PCR assay with a sensitivity of 100 genome copies of MERS-CoV.
Detection of neutralizing antibody in the infectious virus receiving
groups and not the γ-irradiated virus receiving group does suggest
that an infectious process did take place which allowed for antigen
processing for development of neutralizing antibodies.
Artifacts introduced by manipulation of the subjects should be
accounted for by use of control subjects. Control marmosets were
inoculated with media or inactivated virus which also resulted in
limited lung pathology. In the present study, examining the
percent change in diseased lung volume determined a signiﬁcant
difference was observed between the MERS-EMC group and the
mock group, but not between the MERS-EMC and γ-irradiated
group, which suggests that some viral-induced disease process did
occur. However, statistical signiﬁcance was not found when the
Fig. 3. Select clinical parameters through the course of the study. (A) Temperature and peripheral oxygen saturation are within normal values throughout the course of the
study. Respiratory rate is elevated in virus-inoculated groups from day 3 to day 12 post-inoculation. (B) Clinical hematology suggests minimal-to-mild changes throughout
the course of the experiment that remained within normal range (gray shaded area). Black-dashed line indicates mock-inoculated group, blue-dashed line indicates
inactivated-virus-inoculated group, red line indicates MERS-JOR-inoculated group, and black line indicates MERS-EMC-inoculated group.
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total diseased lung volumes were compared between any of the
groups. Across all groups, pathology ﬁndings were predominantly
conﬁned to the lungs showing chronic and resolving changes. The
absence of viral antigen signal in the lung tissue sections by IHC
might be a result of probing for the viral antigen only at a late
stage of disease, when there was likely considerable clearance of
the virus.
Falzarano et al. observed inconsistent lethality highlighted by
lung pathology that shared some characteristics of MERS following
MERS-EMC exposure of common marmosets. Three notable differ-
ences between the present study and Falzarano et al. are 1) our use
of control subjects receiving media or inactivated virus, 2) single IT
route vs. multiple inoculation routes (oral, intranasal, ocular, and
IT), and 3) the volume of lung inoculum (0.2 mL vs. 0.5 mL). Similar
to their rhesus experiment, their marmoset experiment was
designed as a serial euthanasia study. Six subjects were euthanized
at early timepoints post-exposure, before the disease course could
resolve. However, two subjects met moribund endpoint criteria on
day 4, and 3 survived to day 20 post-inoculation. It is unknown
what the true outcome of the subjects that were serially euthanized
would have been and if the subjects that met endpoint criteria did
so due to virus induced disease or subject manipulations, thus
skewing the interpretation of disease severity. Adding to the
difﬁculty in data interpretation, qRT-PCR data is not supported by
immunohistochemistry, EM, or virus isolation. Furthermore, the
pattern of infectious virus isolation shown by Falzarano et al.
demonstrates that initially only the lungs contain infectious virus
in 11/15 tissues (trachea and lung lobes) examined, by day 4 post-
inoculation virus can be isolated from fewer lung lobes (8/10
tissues), but virus can be isolated from the trachea. By day 6 post-
inoculation virus is detected in 1/8 of lung lobes and all tracheas
examined. No quantiﬁcation is provided, therefore it is difﬁcult to
determine if propagated infectious virus was recovered or merely
the inoculum. Based on our data and Falzarano et al.'s data, it is
possible that intratracheal inoculation results in mechanical
damage to the respiratory epithelium, followed by inﬂammation
and repair, which leads to restoration of mucociliary motion that
clears the liquid (and virus) from the lung.
In the absence of a lethal model, other quantitative measures
becomemore valuable for demonstrating pathogenesis. In the present
study, we demonstrated that CT is effective for evaluating disease
progression and regression following MERS CoV exposure in common
marmosets. CT data can be quantiﬁed, which provides an opportunity
to effectively evaluate countermeasures in sub-optimal models and
strengthen data gained in well-established models. In the case of
MERS, an optimal animal model must still be developed. Staged
euthanasia studies similar to the adenovirus transduced mouse MERS
model could be performed in NHPs, but such studies are undesirable
due to the ethical concerns of nonhuman primate use.
Materials and methods
Virus and cells
Vero cells (ATCC catalog number CCL81) were maintained in
Dulbecco's Modiﬁed Eagle's medium (DMEM) (HyClone, Logan,
UT) and supplemented with 10% fetal bovine serum (FBS) (Sigma
St. Louis MO) at 37 1C with 5% CO2. MERS-CoV isolates (Jordan-n3/
2012 and EMC/2012) were propagated at a multiplicity of infection
of 0.1 on Vero cells in 5% FBS and 5% CO2 for 3–4 days post-
inoculation until cytopathic effect encompassed 75–80% of the
Vero cell monolayer. Virus was concentrated by ultracentrifuga-
tion and pelleted through a 20% sucrose cushion at 221,000 g for
2 h at 4 1C. The pellet was re-suspended in DMEM 5% FBS, frozen
and titered by limiting dilution plaque assay (see below). Inacti-
vated virus for the control groups was generated by treating virus
with 60,000 Gy of gamma irradiation from a 60Cobalt irradiator (JL
Shepherd 484-R2), followed by conﬁrmation of inactivation.
MERS-CoV-Jordan-n3/2012 was a kind gift of Armed Forces Health
Surveillance Center, Division of Global Emerging Infections Sur-
veillance and Response System and MERS-CoV-EMC/2012 was
kindly provided by Vincent Munster, Laboratory of Virology,
National Institute of Allergy and Infectious Diseases (NIAID).
Tissue processing and growth curves in primary marmoset cells
Marmoset lung tissue was ground in a sterile petri dish using a
plunger from a sterile syringe, digested with 100 U/ml of collage-
nase (Life Technologies, NY USA), and 10% fetal calf serum (FCS,
HyClone) 37 1C for 30 min. The reaction was quenched, and the
homogenate was passed through a 70-mm ﬁlter, washed, and
centrifuged (500 g, 5 min, 4 1C). After the ﬁnal wash, cells were
re-suspended in 5 ml of ACK Lysing Buffer (Life Technologies) for
15 min and washed twice with 25 ml PBS/5 mM EDTA/0.5% BSA.
Washed and pelleted cells were re-suspended in RPMI (Lonza,
Switzerland) supplemented with 10% FCS (HyClone, UT, USA) and
1% penicillin/streptomycin (PS) and plated. Media was changed
after 24 h. Kidneys were processed similar to the lung but strained
through 70 mm and 40 mm ﬁlters prior to the ACK lysis step.
Bronchoalveolar lavage samples were centrifuged at 1000 g for
10 min at 4 1C, re-suspended in RPMI 10% FCS, and 1% PS (Life
Technologies) before plating. Multi-step growth curves were
performed on isolated primary cells infected with MERS-JOR at a
multiplicity of infection of 0.1. Supernatants were harvested at 0,
24, 48, and 72 h and stored at 80 1C until plaque assays were
performed (described below).
Sequencing of MERS-CoV Spike protein and data analysis
MERS-CoV isolates were sequenced using the primers in Table 2.
Spike genomic sequences were generated by aligning Sanger
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Fig. 4. Fluorescence Reduction Neutralizing Assay. Sera from all subjects was
evaluated for the presence of neutralizing antibody to MERS-CoV as described in
Materials and Methods. Neutralizing antibody could be detected above the back-
ground of the Mock infected subjects (1:10 FRNA50 average) for subjects that
received infectious MERS-CoV, γ-irradiated virus receiving subjects also develop
background (1:10 FRNA50 average) neutralizing antibody.
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Fig. 5. Representative lung CT images demonstrating disease presentation. (A) Comparison of a representative subject from each of the 4 groups at 5 days post-inoculation.
(B) Lung CT of representative subject that received the MERS-EMC isolate throughout the course of the study. Red boxes indicate regions of lung pathology that were ﬁrst
observed at day 3 post-inoculation and persisted to study end. (C) Quantiﬁcation of total diseased lung volume. Black dashed line indicates mock-inoculated group, blue line
indicates inactivated-virus-inoculated group, red line indicates MERS-JOR-inoculated group, and black dashed line indicates MERS-EMC-inoculated group. (D) Fold change
from baseline of diseased lung volume. Black dashed line indicates mock inoculated group, blue line indicates inactivated virus inoculated group, red line indicates MERS-JOR
inoculated group, and black dashed line indicates MERS-EMC inoculated group. (E) Comparison of the mean peak values to the media only instilled group on a total diseased
volume basis. t-Tests were performed, pr0.05 for signiﬁcance. (F) Comparison of the mean peak values compared to the media only group as measured by fold change from
baseline. t-Tests were performed, pr0.05 for signiﬁcance.
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sequences against either MERS-JOR or MERS-EMC spike reference
sequences obtained from GenBank (MERS-JOR: KC776174, MERS-
EMC: JX869059). To generate a comparison between study stocks
and references, spike sequences obtained from sequencing and
associated reference sequences were aligned using Clustal Omega
with default settings (Goujon et al., 2010; McWilliam et al., 2013;
Sievers et al., 2011). The resulting clustal alignment was ﬁltered for
alignment positions with at least one variant base using a custom
Python script. Potential coding changes were assessed by BLASTX
alignments (Altschul et al., 1990).
Challenge and monitoring of NHPs
Ten common marmosets, ranging in weight from 250 g to 475 g
and age from 3 to 9 years were divided into 4 groups. Mock
inoculated subjects (n¼2) received DMEM supplemented with 5%
FBS by IT inoculation. Two subjects received inactivated virus by IT
inoculation; one subject received inactivated MERS-JOR virus
isolate, and one subject received inactivated MERS-EMC virus
isolate. Three marmosets received 5107 PFU of MERS-JOR and
3 others received 5107 PFU of MERS-EMC by IT inoculation. Prior
to handling, marmosets were anesthetized with isoﬂurane to
effect. IT inoculation was performed by placement of a 20
gauge1 in. catheter into the trachea followed by installation of
the virus inoculum in a 0.2 mL volume followed by a 0.2 mL air
ﬂush of the syringe and catheter. All animal procedures were
approved by the National Institute of Allergy and Infectious
Diseases (NIAID) Animal Care and Use Committee, and adhered
to National Institutes of Health (NIH) policies. The experiments
were carried out at the NIAID Integrated Research Facility, an
AAALAC and AALAS accredited facility.
Prior to and after inoculation, CT scans, physical exams,
including temperature and weight measurements were per-
formed, oropharyngeal and rectal swabs, and stool samples were
collected (Fig. 2). NHPs were monitored at least twice daily. A pre-
established scale was used to evaluate subject health and disease
progression. These criteria included: (1) overall clinical appear-
ance, (2) labored breathing, (3) activity and behavior, (4), respon-
siveness, and (5) core body temperatures. No subjects met
moribund clinical endpoint criteria by study end. Eight of 10
marmosets were humanely euthanized for histopathological and
virological analysis. Blood withdrawal was performed pre-inocu-
lation, either day 4 or 5 post-inoculation, and at necropsy.
Computed tomography and image analysis
We acquired high resolution chest CT scans, without contrast,
using a hybrid Philips Gemini 16 slice PET/CT scanner speciﬁcally
designed to function in a Biological Safety Level 4 environment.
Due to the rapid respiratory rate of marmosets, a breath hold could
not be performed. The CT parameters were as follows: helical scan,
140 kVp, 300 mA s, 90 mm ﬁeld of view, 0.5 mm/rotation table
speed, high-resolution collimation of 160.75 mm2, 0.8 mm slice
thickness, and 0.4 mm increment covering the whole lung. The
images were acquired using a standard algorithm and recon-
structed using a Y-detail algorithm. Images were analyzed as
Fig. 6. Gross and Histopathology. (A) Gross lung pathology demonstrating mostly normal lung with multifocal to coalescing moderate interstitial pneumonia in the left
caudal lung lobe. (B) Low magniﬁcation of lung ﬁeld from MERS-CoV EMC inoculated subject demonstrating pneumonia. (C) High magniﬁcation of lung ﬁeld from a MERS-
CoV-EMC-inoculated subject with evidence of pneumonia; interstitial lymphohistiocytic neutrophilic with type II pneumocyte hyperplasia (red arrow), and extramedullary
hematopoiesis (Black arrow). (D) High magniﬁcation of a lung ﬁeld from a MERS-CoV EMC infected subject demonstrating pneumonia with interstitial, neutrophilic with
type II pneymocyte hyperplasia and ﬁbrosis (*).
Table 2
MERS-CoV Spike primers for ampliﬁcation and sequencing.
Primer
name
Sequence Location relative to Spike AUG
start codon
Fw 1 MERS
SPIKE
GTAATATCTCTCCTGTCGCAG 43
Rv 2 MERS
SPIKE
GCTCTGCGTATATAACCATCAAC 194
Fw 2 MERS
SPIKE
GTATGTTGATTTGTACGGCG 1007
Rv 3 MERS
SPIKE
CGCAATTGCCTAATTGAGAG 807
Fw 3 MERS
SPIKE
CATGACTGAGCAATTACAGATG 1810
Rv 4 MERS
SPIKE
CTGCCAGTAGATATAGAAACAGG 1686
Fw 4 MERS
SPIKE
CCAGGATGATTCTGTACG 2648
Rv 5 MERS
SPIKE
CTATATGTGTGCCTTGACCG 2523
Fw 5 MERS
SPIKE
CAACGTCTTGATGTTCTCG 3370
Rv 6 MERS
SPIKE
GCAGTGACCAAAAGAGAG 3166
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previously described (Via et al., 2013). Unpaired t-test of peak
abnormal lung volume was performed with Graphpad Prism 6.0
(GraphPad Software, CA, USA).
Hematology and serology
Complete blood cell differential count was determined from
blood samples collected in EDTA-coated blood tubes and analyzed
using a Sysmex XT2000V™ hematology analyzer (Sysmex America).
Quantiﬁcation of viremia by quantitative RT-PCR
Viral load in samples was determined by quantitative PCR using
the following primer probe set: forward primer: 5ʹTGGCC
GTGGTGGTTATCACT 3ʹ, reverse primer: 5ʹCTCAAAATCGTCCATCCA
CTCA3ʹ, and probe 5ʹ6-FAM/CACCCCATTCCACTATGAGCGAGACAAC/
36-TAMSp/3ʹ. Cycling conditions were 48 1C for 30 min and 95 1C
for 10 min for the RT-step followed by 95 1C for 15 s and 60 1C for
60 s for 40 cycles. The TaqMan One-Step RT-PCR Master Mix was
used (Life Technologies, NY, USA). Samples were extracted with
Trizol and screened for the presence of MERS-CoV using speciﬁc
primers on an Applied Biosystems 7900HT fast real time PCR
system (Life Technologies). The limit of detection was 100 gene
copies.
Plaque assay and FRNA50
Virus stock and tissue samples were excised at necropsy, ﬂash
frozen, and stored at 80 1C. For tissues, a w/v homogenate
between 10% and 30% was generated. Serial 10-fold dilutions were
made for virus stocks, growth curve samples, and tissues and
incubated on conﬂuent VeroE6 cells using 0.8% tragacanth in
EMEM 2% FBS, and 1% PS overlay and incubated for 5 days.
Following incubation, tragacanth overlays were removed, the
monolayers were stained with crystal violet (0.1% crystal violet,
20% ethanol 10% formalin v/v), and plaques were enumerated.
Serum samples taken at necropsy or experiment end were heat
inactivated at 56 1C for 1 h then serial diluted and mixed with
120 PFU (ﬁnal MOI¼1.0) of either MERS-JOR or MERS-EMC and
incubated for 1 h. After incubation virus and serum mixture was
added to VeroE6 cells (ATCC, Manassas VA) for 1 h at 37 1C, 5% CO2
on 96 well Operetta (Perkin-Elmer) compatible plates. Negative
control (no virus and no serum) samples and positive control
(virusþrabbit polyclonal antibody to the MERS Spike protein (Sino
Biological)) samples were also included. Cells were washed and
incubated for 24 h followed by ﬁxation with 20% NBF. MERS-CoV
infection was visualized by ﬂuorescence using a MERS-CoV anti-
Spike antibody (Sino Biological) on an Operetta High Content
Imager (Perkin-Elmer). The dilution at which 50% inhibition of
relative ﬂuorescence intensity was observed was reported as the
FRNA50.
Histopathology and immunohistochemistry
Forty-one tissues from all major organ systems were collected
and ﬁxed in 10% neutral buffered formalin (NBF) for 30 days.
Following ﬁxation in 10% NBF tissues were processed following
standard procedures. Hematoxylin and eosin (HE) stain was
applied using the Leica automated staining system (Leica, Micro-
systems). Stained slides were then examined via standard light
microscopy. To detect MERS-CoV antigen, IHC was performed
using a rabbit polyclonal antiserum against MERS-CoV (Sino
Biological P.R. China) (1:1000). Tissues from an uninfected control
animal were used to validate all IHC procedures. HE and IHC
sections were examined by light microscopy by the veterinary
pathologists (SY and LH).
Author summary
In this experiment, we sought to determine if there were virus
speciﬁc differences in disease progression following intratracheal
inoculation of common marmosets with Middle Eastern Respira-
tory Syndrome Coronavirus, commonly known as MERS-CoV, with
two common laboratory viral isolates (MERS-EMC and MERS-
Jordan). In contrast to previous results, we observed a non-lethal
disease and few, if any, signs of virus-speciﬁc pathology. In
addition, we were unable to isolate infectious virus from tissues.
Computed tomography was used to evaluate disease progression
and provide quantitative data for comparisons between mock-
exposed, inactivated virus-exposed, and virus-exposed subjects.
The data indicate that marmosets do not faithfully replicate
human MERS pathogenesis and that alternate models must be
developed to efﬁcacy test medical countermeasures.
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